
- /
- Supported exchanges
- / US
- / PLSE.NASDAQ
Pulse Biosciences Inc (PLSE NASDAQ) stock market data APIs
Pulse Biosciences Inc Financial Data Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pulse Biosciences Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pulse Biosciences Inc data using free add-ons & libraries
Get Pulse Biosciences Inc Fundamental Data
Pulse Biosciences Inc Fundamental data includes:
- Net Revenue: -9 000
- EBITDA: -71 098 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pulse Biosciences Inc News

Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
Pulse Biosciences PLSE recently reached a key milestone with the FDA’s approval of its Investigational Device Exemption (IDE) to initiate the NANOCLAMP AF study, evaluating its Nanosecond Pulsed Fie...


Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
Pulse Biosciences PLSE recently reached a key milestone with the FDA’s approval of its Investigational Device Exemption (IDE) to initiate the NANOCLAMP AF study, evaluating its Nanosecond Pulsed Fie...

PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Pulse Biosciences PLSE has announced the publication of its first-in-human clinical feasibility study in the Journal Thyroid, highlighting the effectiveness of its proprietary Nanosecond Pulsed Field ...

Pulse Biosciences reports success in thyroid nodule treatment study
HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.11 billion market cap medical technology company with strong liquidity metrics, announced that a first-in-human clinical feasibility study...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.